SPL 0.00% 9.7¢ starpharma holdings limited

Ann: DEP irinotecan outperforms in pancreatic cancer model, page-20

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 357 Posts.
    lightbulb Created with Sketch. 31
    I guess they will scale up the dosage with the Colon cancer patients and then when they near the maximum tolerated dose they can use it with the Pancreatic cancer patients.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.